Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | TNKS | O95271 | 5/20 | 0.37 |
| ▸ | ADCY1 | Q08828 | 3/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774755 | 1.00 | BTK (0.41) | BTKEPHX2CCR5SMYD3LIPG | |
| SCHEMBL517164 | 0.82 | TNKS (0.44) | EPHX2SMYD3LIPGTNKSADCY1 | |
| SCHEMBL517165 | 0.82 | TNKS (0.44) | EPHX2SMYD3LIPGTNKSADCY1 | |
| SCHEMBL21733956 | 0.82 | LIPG (0.49) | BTKLIPG | |
| SCHEMBL30216265 | 0.82 | LIPG (0.49) | BTKLIPG | |
| SCHEMBL8226321 | 0.80 | — | — | |
| SCHEMBL408297 | 0.80 | CCR5 (0.40) | BTKEPHX2CCR5ADCY1ADCY8 | |
| SCHEMBL441460 | 0.80 | CCR5 (0.40) | BTKEPHX2CCR5ADCY1ADCY8 | |
| SCHEMBL441026 | 0.79 | PKM (0.39) | BTKEPHX2CCR5ADCY1ADCY8 | |
| SCHEMBL408403 | 0.79 | PKM (0.39) | BTKEPHX2CCR5ADCY1ADCY8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | BTK 1916/4885EPHX2 1793/4885CCR5 1166/4885 |
| US-20200071333-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | BTK 1916/4885EPHX2 1793/4885CCR5 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.